Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Atai Life Sciences N.V.
Industry Sector: HealthTechnology
CEO: Srinivas G. Rao, MD, PhD
Number Of Employees: 54
Enterprise Value: $165,645,832
PE Ratio: -1.63
Exchange/Ticker 1: NASDAQ:ATAI
Exchange/Ticker 2: N/A
Latest Market Cap: $293,492,896
BioCentury | Nov 8, 2024
Management Tracks
Moderna expands executive committee, moves commercial under Hoge
Plus: New CFOs at Alkeus, ClaciMedica, and updates from Clairity and Kincell
BioCentury | Aug 17, 2024
Product Development
How the next psychedelics companies believe they can avoid Lykos’ fate
Functional unblinding, expectation bias are surmountable hurdles
BioCentury | Feb 8, 2024
Management Tracks
New chair, CFO for I-Mab as part of U.S. push
Plus: Artios hires Silverstein as CFO and updates from Astellas, atai, Cartography, Corvus and Helio
BioCentury | Jan 24, 2024
Data Byte
Schizophrenia pipeline: two PDUFA dates and a dozen readouts in 2024
A look ahead to the schizophrenia milestones coming this year, and the mechanisms behind them
BioCentury | Aug 19, 2023
Product Development
Psychedelic pipeline moves toward proof of concept
But the field’s biggest question won’t be answered for a while: whether it’s possible to take the psychedelic out of psychedelics
BioCentury | Nov 30, 2022
Management Tracks
ATAI hires new CBO
Plus: Haag-Molkenteller becomes CMO at EG427, and an update from Quris
BioCentury | Oct 21, 2022
Data Byte
Addiction drug development activity doesn’t reflect the need
Innovative targets, approaches are breaking through, but clinical landscape remains vastly underpopulated
BioCentury | Jun 30, 2022
Management Tracks
FDA names Bumpus chief scientist, Marston CMO
Plus Beyer becomes CEO at Kures, and updates from NGM, Apexigen, Achilles and more
BioCentury | Oct 21, 2021
Data Byte
Europe’s largest venture rounds of the year
Europe’s top 13 biotech venture financings this year have raked in a combined $2B
BioCentury | Oct 14, 2021
Emerging Company Profile
Alto: a computational, biomarker-based approach to neuropsychiatry
Stanford spinout uses algorithm to match previously studied treatments with patient populations
Items per page:
1 - 10 of 11